Metraipolis › archive › dc_76751cf7c893

Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens — Europe PMC PMID:41471096

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41471096
DOI
10.3390/pharmaceutics17121581
License (as archived)
solo-consultazione
Archived
2026-11-07T19:31:00.736Z
SHA-256 of the archived text
4138a6f8805de4040d59cb569a79e58ae67600ef4fb5b32428d21c5133dc9971
Stable URL of this page
https://metraipolis.com/documento/dc_76751cf7c893

How to cite

Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens — Europe PMC PMID:41471096 — Europe PMC (en), https://europepmc.org/article/MED/41471096 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_76751cf7c893 (Metraipolis archive dc_76751cf7c893, sha256 4138a6f8805de4040d59cb569a79e58ae67600ef4fb5b32428d21c5133dc9971)
BibTeX
@misc{dc76751cf7c893,
  title = {Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens — Europe PMC PMID:41471096},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41471096},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_76751cf7c893; sha256 4138a6f8805de4040d59cb569a79e58ae67600ef4fb5b32428d21c5133dc9971},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41471096. Agents can read the archived copy with the MCP tool read_document.